Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies

Video

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Whether BTK inhibitors have to be given continuously to maintain their efficacy remains unanswered, says Burke. Moreover, the majority of trials to date have evaluated indefinite BTK inhibitor therapy.

However, continuous BTK inhibitor treatment can cause additive toxicities over years, as well as added cost to the health care system, Burke explains. Additionally, many patients prefer to stop therapy rather than continue on the drug indefinitely.

Stopping therapy after patients achieve an early clinical benefit appears to be an ideal approach to BTK inhibitor treatment, Burke says.

Currently, trials are evaluating novel combinations to see if patients can achieve deeper remissions and then stop therapy with favorable outcomes, Burke concludes.

Recent Videos
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.